TY - JOUR
T1 - Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese
AU - Chan, KH
AU - Ramsden, David
AU - Yu, YL
AU - Kwok, KHH
AU - Chu, ACY
AU - Ho, PWL
AU - Kwan, JSC
AU - Lee, R
AU - Lim, E
AU - Kung, MHW
AU - Ho, SL
PY - 2009/3/1
Y1 - 2009/3/1
N2 - Idiopathic inflammatory demyelinating disorders (IIDD) affect the central nervous system. In classical multiple sclerosis (CMS), brain, optic nerves [optic neuritis (ON)] and spinal cord [acute transverse myelitis (ATM)] are affected. In neuromyelitis optica (NMO), optic nerves and spinal cord are predominantly affected. NMO-IgG, an autoantibody targeting aquaporin-4, is a marker for NMO. We studied the frequency and clinical relevance of NMO-IgG seropositivity in IIDD patients.
Neuromyelitis optica-IgG was detected by indirect immunofluorescence using primate cerebellum.
Neuromyelitis optica-IgG was detected in six of 10 NMO patients (60%), six of 10 idiopathic relapsing transverse myelitis (IRTM) patients (60%), two of nine idiopathic relapsing ON patients (22%), one of 11 patients (9%) having single ON attack, one of 30 CMS patients (3%), and none of patients having single ATM attack or controls. Comparing NMO-IgG seropositive (n = 12) with NMO-IgG seronegative (n = 8) patients having NMO or IRTM, NMO-IgG seropositivity was associated with a higher relapse rate in first 2 years, 1.5 and 0.6 attacks/year for seropositive and seronegative groups respectively (P = 0.006), and non-significant trend towards more severe ON and myelitis with poorer clinical outcome.
Neuromyelitis optica -IgG facilitates diagnosis of NMO spectrum disorders. NMO-IgG seropositivity is associated with higher relapse rate in first 2 years.
AB - Idiopathic inflammatory demyelinating disorders (IIDD) affect the central nervous system. In classical multiple sclerosis (CMS), brain, optic nerves [optic neuritis (ON)] and spinal cord [acute transverse myelitis (ATM)] are affected. In neuromyelitis optica (NMO), optic nerves and spinal cord are predominantly affected. NMO-IgG, an autoantibody targeting aquaporin-4, is a marker for NMO. We studied the frequency and clinical relevance of NMO-IgG seropositivity in IIDD patients.
Neuromyelitis optica-IgG was detected by indirect immunofluorescence using primate cerebellum.
Neuromyelitis optica-IgG was detected in six of 10 NMO patients (60%), six of 10 idiopathic relapsing transverse myelitis (IRTM) patients (60%), two of nine idiopathic relapsing ON patients (22%), one of 11 patients (9%) having single ON attack, one of 30 CMS patients (3%), and none of patients having single ATM attack or controls. Comparing NMO-IgG seropositive (n = 12) with NMO-IgG seronegative (n = 8) patients having NMO or IRTM, NMO-IgG seropositivity was associated with a higher relapse rate in first 2 years, 1.5 and 0.6 attacks/year for seropositive and seronegative groups respectively (P = 0.006), and non-significant trend towards more severe ON and myelitis with poorer clinical outcome.
Neuromyelitis optica -IgG facilitates diagnosis of NMO spectrum disorders. NMO-IgG seropositivity is associated with higher relapse rate in first 2 years.
KW - idiopathic inflammatory demyelinating disorders
KW - classical multiple sclerosis
KW - neuromyelitis optica
KW - idiopathic relapsing transverse myelitis
KW - longitudinally extensive transverse myelitis
KW - neuromyelitis optica-IgG
U2 - 10.1111/j.1468-1331.2008.02376.x
DO - 10.1111/j.1468-1331.2008.02376.x
M3 - Article
C2 - 19138340
SN - 1468-1331
SN - 1468-1331
SN - 1468-1331
SN - 1468-1331
SN - 1468-1331
SN - 1468-1331
SN - 1468-1331
VL - 16
SP - 310
EP - 316
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 3
ER -